November 2023

ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years.ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metast

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: